Organization
Hutchison MediPharma Limited
28 clinical trials
Clinical trial
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH MutationsStatus: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid TumorsStatus: Completed, Estimated PCD: 2023-04-25
Clinical trial
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in EuropeStatus: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
A Phase I, Multicenter, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-A83 in Patients With Advanced Malignant NeoplasmStatus: Recruiting, Estimated PCD: 2025-06-07
Clinical trial
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) MutationsStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 1, Open-Label, 4-Part, Fixed-Sequence Study to Assess the Effect of Itraconazole, a Strong CYP3A Inhibitor, the Effect of Fluconazole, a Moderate CYP3A/2C9 Inhibitor, the Effect of Rifampin, a Strong CYP3A Inducer, and the Effect of Rabeprazole, a Proton Pump Inhibitor on the Pharmacokinetics of HMPL-689 in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-08-06
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine TumorsStatus:
Clinical trial
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of HMPL-506 in Patients With Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2027-10-08
Clinical trial
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2027-08-31
Clinical trial
A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status: Not yet recruiting, Estimated PCD: 2027-06-03
Clinical trial
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients With Advanced Malignant Solid TumorStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-08-28
Clinical trial
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Post-Marketing Clinical Study to Evaluate the Safety of Elunate® (Fruquintinib Capsules) in Chinese Patients.Status: Completed, Estimated PCD: 2022-09-27
Clinical trial
A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-09-22
Clinical trial
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-13
Clinical trial
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, and the Effect of Rifampin on the Pharmacokinetics of HMPL-523 in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-02-05
Clinical trial
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)Status: Withdrawn, Estimated PCD: 2022-11-16
Clinical trial
A Phase 1, Open-label, 2-part, 2-period Fixed-sequence Study to Evaluate the Effect of Fruquintinib on the Pharmacokinetics of Dabigatran Etexilate (A P-GP Substrate) and Rosuvastatin (A BCRP Substrate) in Healthy SubjectsStatus: Completed, Estimated PCD: 2022-04-22
Clinical trial
An Open-Label, Single-Arm, Multicenter Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusion/RearrangementStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-Label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of FruquintinibStatus: Completed, Estimated PCD: 2022-10-25
Clinical trial
Single-center, Open-label, Multi-dose Study to Investigate the Human Mass Balance in Healthy Adult Male Following Multiple Oral Doses of HMPL-523 Tablets Followed by a Single Oral Dose of 300 mg/150 µCi [14C]HMPL-523 SuspensionStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
An Open-Label, Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of FruquintinibStatus: Completed, Estimated PCD: 2023-06-26
Clinical trial
A Phase Ib/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-01